• Français (FR)
  • English (UK)
  • Home
  • Company
    • About us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
      • Partnerships
  • Nox Science
    • NOX Enzymes
      • NADPH Oxidase
      • NOX Enzyme Family
      • NOX Expression
    • NOX and Disease
      • Oxidative Stress and Disease
      • Physiological Functions of NOX
      • Fibrotic diseases
      • Neurodegenerative diseases
      • Cardiovascular diseases
    • Publications
  • Pipeline
    • Setanaxib
    • Preclinical NOX1 program
    • Research programs
  • Investors
    • Stock information
    • Analyst coverage
    • Contribution project
      • Press release
      • Project presentation
      • Documentation
      • Shareholders general meeting
    • Press releases
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Events and presentations
    • Regulated information
      • Financial information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2015
        • 2014
      • Other regulated information
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
      • Governance
      • OCABSA warrants
    • Shareholder information
      • Shareholders’ meetings
        • 2021
        • 2020
        • 2019
          • AGM of June 13, 2019
          • AGE of January 2019
        • 2018
          • AGM of june 13, 2018
        • 2017
          • AGM of June 15, 2017
          • AGM of February 28, 2017
        • 2016
        • 2015
        • 2014
      • Agenda
  • News and Events
    • Press releases
    • Events and presentations
    • Media
      • Press clippings
      • Interviews
  • Contacts
  • Capital Increase
  • News and Events /
  • Events and presentations

Events and presentations

2020-05-28 - 11:00

Investor Presentation May 2020

2019-07-25 - 13:30

Conference call July 25 2019 – Inhibiting NOX enzymes to treat multiple diseases with high medical need

2019-07-24 - 19:00

Genkyotex conference call on July 25, 2019 at 2 pm CEST

2019-07-03 - 12:00

Genkyotex invitation to Biotech Agora in Paris on July 10, 2019

2019-05-02 - 13:00

Phase 2 trial of GKT831 in patients with primary biliary cholangitis Top line final results

2019-04-24 - 14:00

ILC2019 Presentation – GKT831 Phase 2 in PBC

2018-11-05 - 15:00

Management presentation on positive interim Phase 2 results in PBC

  • Press releases
  • Events and presentations
  • Media
    • Press clippings
    • Interviews

Ask us your questions

Suscribe to Newsletter

  • Legal terms

Back to Top

© 2021 genkyotex.com